SETD2 prediction yielded AUROCs of 0.895 (0.827–0.951, p = 0.035) in PRAD. KRAS mutations were predictable with an AUROC of 0.918 (0.844–0.979, p < 0.001) in KIRP. Here, SETD2 is linked to prostate adenocarcinoma.